Stephanie Fradette, PharmD, is a Vice President and Head of the Neuromuscular Development Unit at Biogen. In her role, she oversees development of therapies for a variety of neuromuscular diseases, including Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and Friedreich’s Ataxia (FA). Stephanie has spent the last 14 years in various roles across Research and Development, including Safety, Regulatory, and Clinical Development. Recently, she led the development of the first approved therapy for a genetic form of ALS (SOD1-ALS), which supported significant advancement of neurofilament as a biomarker and optimization of clinical trial design in ALS. Prior to her work in ALS, she was the Global Regulatory Lead for SPINRAZA, the first approved therapy for spinal muscular atrophy (SMA).